Navigation Links
Etirinotecan Pegol (NKTR-102) Passes Interim Efficacy Analysis for BEACON Pivotal Phase 3 Clinical Study in Patients with Metastatic Breast Cancer
Date:1/14/2014

onia. Additional development-stage products that leverage Nektar's proprietary technology platform include Baxter's BAX 855, a longer-acting PEGylated rFVIII program, which is completing Phase 3 clinical development.

Nektar's technology has enabled eight approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia. 

Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India.  Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

Cautionary Note Regarding Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," "could," "potential," "may" and similar references to future periods. Examples of forward-looking statements include our current views regarding the potential of etirinotecan pegol as a potential new therapy for patients with metastatic breast cancer that have failed other available therapies; the estimated timeline for the availability of top-line data from the BEACON clinical study and, if the study is successful, the timing of regulatory filings with health authorities; the value of our polymer conjugate technology platform; and the potential of certain of our other drug candidates and those of our collaboration partners. Forward-looking statements are neither historical facts nor assuranc
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer
2. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
3. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
4. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
5. CAS REGISTRY(SM) surpasses 75 million small molecules
6. WuXi Manufacturing Facility Passes FDA Inspection
7. Tecfideras Patient Share at Three Months Postlaunch Surpasses That for Aubagio and Gilenya At the Same Stage of Their Launches
8. Emotivs Brainwear Technology To Track Cognitive Health Surpasses $1M Kickstarter Stretch Goal
9. The Leukemia & Lymphoma Society Co-Pay Assistance Fund Surpasses $200 Million
10. French Man with SynCardia Total Artificial Heart Surpasses Two Years of Support
11. NABPs .PHARMACY Proposal Passes Initial ICANN Evaluation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 The Competitive ... regulatory and marketplace changes. CI leaders who adjust will ... In a new Best Practices, LLC study CI ... actionable insights, including: - Use secondary research ... primary research - Internal staff who are ...
(Date:8/29/2014)... , Aug. 29, 2014  A Boston Scientific ... study on stent removability and preliminary long term ... published in the August issue of the peer-reviewed ... 1 is being conducted in 11 countries ... covered self-expanding metal stents (FCSEMS) after extended indwell ...
(Date:8/29/2014)... Calif. , Aug. 29, 2014 Thoratec ... in device-based mechanical circulatory support therapies to save, support ... participating in the 2014 Morgan Stanley Global Healthcare Conference ... Burbach , President and Chief Executive Officer, will provide ... Eastern Daylight Time (9:55 a.m., Pacific Daylight Time).   ...
Breaking Medicine Technology:Using the Competitive Intelligence Function to Drive Better Business Decisions in the Pharmaceutical Sector 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 3Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 4
... England and TOKYO, June 29 , ... Sosei Group Corporation ("Sosei"; TSE Mothers ... commencement of a Phase III,clinical study by Novartis, with NVA237, ... obstructive pulmonary disease,(COPD). NVA237 is a dry powder formulation for ...
... and New Genetic Mutations Acting Together-- , , ... autism inheritance puzzle are emerging in the latest study ... Hospital of Philadelphia, the University of Pennsylvania ... identified 27 different genetic regions where rare copy number ...
Cached Medicine Technology:Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 2Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 3Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 4More Gene Mutations Linked to Autism Risk 2More Gene Mutations Linked to Autism Risk 3More Gene Mutations Linked to Autism Risk 4
(Date:8/30/2014)... August 30, 2014 McLeod's Sunset Park ... auto repair shop with strong ties to the community celebrates ... happy to announce they have been chosen by The ... for auto repair. , Tim McLeod’s father, Norris (most ... sixty years ago. Although his son, Tim runs the day ...
(Date:8/30/2014)... Franklin, TN (PRWEB) August 30, 2014 ... techniques, including nine mobilizations and six muscle energy techniques. ... also narrates and demonstrates twenty-seven examination techniques for the ... course supports Dr. Reiman's live course presentation with ... Objectives, Applying a differential diagnosis ...
(Date:8/30/2014)... August 30, 2014 What challenges exist ... are the latest trends, concerns, and considerations? Sports ... Ken Pendleton recently spoke with Woody Wommack, Southeast Football ... current issues in football recruiting. Notably, Wommack spoke ... athletes, changes that he thinks are coming as a ...
(Date:8/30/2014)... A new sudden death predictor for patients with ... defibrillators (ICDs) in ESC Guidelines published today. They ... Chairperson Professor Perry Elliott (UK). , The "2014 ... Cardiomyopathy" are published today on-line in the ... ESC Website. Previous ESC Guidelines on hypertrophic cardiomyopathy ...
(Date:8/29/2014)... San Diego (PRWEB) August 30, 2014 ... and their loved ones and caretakers. Author Eddie M. Leung ... with cholangiocarcinoma or bile duct cancer, a very ... “The Year That Changed My Life” (published by Xlibris), he ... but more importantly, he imparts a survivor’s testimony that this ...
Breaking Medicine News(10 mins):Health News:McLeod's Sunset Park Auto Service Celebrates 60 Years Honored with Best of South Tampa 2Health News:North American Seminars Online PT Continuing Education Course, Examination and Treatment of the SI Joint, Receives Continuing Education Approval in NJ, CA, IL, PA, & TX 2Health News:Woody Wommack of Rivals.com Discusses the World of NCAA Football Recruiting on SCI TV 2Health News:Woody Wommack of Rivals.com Discusses the World of NCAA Football Recruiting on SCI TV 3Health News:Sudden death predictor identifies ICD candidates in new ESC Guidelines 2Health News:Eddie M. Leung Shares His Testimony As a Survivor of Cancer 2Health News:Eddie M. Leung Shares His Testimony As a Survivor of Cancer 3
... a roadside and rushed to the University of Rochester Medical Center ... doctors were surprised to discover that a trendy tea derived from ... URMC team reported the case study, believed to be the first ... Journal of Emergency Medicine . They described it as ...
... FL (For immediate release) -- Cotinine, a compound derived from ... in a mouse model of Alzheimer,s disease, a study led ... University of South Florida found. The findings are ... in advance of print publication. "We found a compound ...
... the manufacturer of the Alzheimer,s drug memantine submitted a supplementary ... Efficiency in Health Care (IQWiG) sees proof of a benefit ... of a benefit for activities of daily living, at least ... conclusions of the first IQWiG benefit assessment of 2009. IQWiG ...
... Colonoscopy is regarded as the most thorough way ... life-saving procedure can also be painful. Scientists and ... to reduce patient discomfort while also ensuring the ... School of Engineering led by Associate Professor of ...
... Pain researchers from the Sheikh Zayed Institute for Pediatric ... that resiniferatoxin, a drug that has shown early promise as ... body,s ability to fight off bacterial infections, particularly sepsis. ... of the journal Anesthesiology , sheds new light on ...
... percent of American families living above the federal poverty ... the Affordable Care Act, according to a new Commonwealth ... the Massachusetts Institute of Technology (MIT). The report finds ... under the law will make premiums affordable for most ...
Cached Medicine News:Health News:Medical sleuthing linked muscle, kidney problems to kava tea 2Health News:Medical sleuthing linked muscle, kidney problems to kava tea 3Health News:Tobacco-derived compound prevents memory loss in Alzheimer's disease mice 2Health News:Long struggle for appropriately processed manufacturer data leads to a new assessment of memantine 2Health News:Long struggle for appropriately processed manufacturer data leads to a new assessment of memantine 3Health News:A less painful colonoscopy 2Health News:A less painful colonoscopy 3Health News:Study: Resiniferatoxin may increase sepsis-related mortality 2Health News:New study: Health reform to make health insurance affordable for nearly all families 2
The ACE Alera clinical chemistry system serves a wide variety of chemistry diagnostic needs with the power of a large floor model analyzer in an easily integrated and economizing compact footprint of...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: